Hemanua Limited based in Dublin & Waterford in Ireland, was formed with the objective of researching, designing, developing, and bringing to commercialisation  innovative life-saving blood separation technologies based on the core patented platform of mircofibre blood filtration technology.

The origin of the company, based on the concept of inbound innovation, was created following the acquisition of the intellectual property and assets of Hemacon GmbH (Germany)  completed in  July 2104.

Hemanua  today is funded by a group of both Irish and international private investors.